ReviewMolecular biology reports2026
Neuroimmune mechanisms in PTSD: inflammatory heterogeneity, circuit dysfunction, and biomarker-based subtypes.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-traumatic stress disorder (PTSD) is characterized by exaggerated fear response, anxiety, hyperarousal and sleep disturbances. One of the major pathophysiological mechanisms underlying the development of PTSD is the dysregulation of the hypothalamic-pituitary-adrenal axis. However, the molecular and cellular mechanisms underlying the development of the disease remain poorly understood due to the heterogeneity of the clinical symptoms and disease course. There is emerging evidence that peripheral immune signaling, endocrine regulation, and glial-vascular interactions play a role in modulating neural circuit functions, which in turn can impact synaptic plasticity and network dynamics. In this review, we integrate evidence from cytokine and immune cell profiling, epigenetic and transcriptomic analyses, experimental immune activation studies. We elaborated neuroimaging, including the translocator protein-positron emission tomography (TSPO-PET) as a marker of glial activation state, to summarize the potential role of immune-brain interactions in modulating circuit and network phenotypes in PTSD. Recently, studies emphasized the role of inflammatory biomarkers, such as C-reactive protein (CRP), interleukin-6 (IL-6), Tumor necrosis factor-alpha (TNF-α), as well as changes in monocyte and T-cell phenotypes, in PTSD. In this review, we focus on the neuroimmune interface in PTSD, including immune-activated and immune-altered phenotypes that may relate to different underlying dysfunctions in neural circuits. We also elaborated the interactions between immune signaling, endocrine control, and neural networks that may trigger clinical heterogeneity in PTSD. Notably, future studies that incorporate peripheral markers with multimodal neuroimaging will be critical for validating these underlying mechanisms.
Indexed as
Identifiers
42313200What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.